A study of Duvelisib, an oral medicine to treat Peripheral T Cell Lymphoma (PTCL)Research Question:
What is the effect of oral medicine, duvelisib, in patients with relapsed or refractory
Peripheral T cell Lymphoma (PTCL)?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This is a multi-center, open-label study of duvelisib (brand name Copiktra), an oral
medicine to treat patients with relapsed or refractory Peripheral T cell Lymphoma
Study Reference #: ILYM-17121
Lead Researcher (Principal Investigator)
Lead Researcher: Carla Casulo
Study Contact InformationStudy Coordinator: Yelena Lerman
Phone: (585) 276-8333
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search